June 09, 2026
2 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Dihydropyridine calcium channel blockers tied to worse kidney outcomes in type 2 diabetes
Dihydropyridine calcium channel blockers may be linked to worse kidney outcomes for patients with type 2 diabetes, according to study data presented at the European Renal Association Congress in Glasgow, Scotland. Dihydropyridine calcium channel blockers (DCCBs) are a commonly prescribed antihypertensive medication for patients with diabetic kidney disease, according to Timna Agur, MD, senior
795 words~4 min read
